Ozempic and Wegovy make the list of the next 15 drugs in Medicare negotiations: HHS
Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer treatment Calquence, GSK’s chronic obstructive pulmonary disorder (COPD) drug Breo Ellipta, and AbbVie’s antipsychotic medication Vraylar.
Hosted on MSN1h
HHS Announces 15 More Drugs for Medicare Price Negotiations in Final Days of Biden-Harris AdministrationIn the final days of the Biden-Harris Administration, the U.S. Department of Health and Human Services (HHS) last week ...
Meena Seshamani’s Medicare swan song ended on a note of bravura: the announcement that 15 costly drugs, including Novo ...
The rescinded order directed Medicare and Medicaid to test ways to lower drug costs for enrollees. Those tests hadn’t started ...
Abe Sutton, a health policy aide in the first Trump administration, is likely to be named head of the Center for Medicare and ...
1. Mr. Trump announced in November 2024 that Robert F. Kennedy Jr., son of former Attorney General Robert F. Kennedy and nephew to President John F. Kennedy, is his pick for HHS Secretary. Mr. Kennedy ...
Paul Mango, a senior health official during President-elect Donald Trump's first term who was a member of Trump's current ...
As of Monday, FDA commissioner Robert Califf, Department of Health and Human Services (HHS) Secretary Xavier Becerra, ...
HHS told the Second Circuit that Boehringer Ingelheim’s voluntary participation in Medicare negotiations “undermines” its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback